Memorandum by Head of Policy Development,
Royal Pharmaceutical Society of Great Britain (PI 16)
INQUIRY INTO THE INFLUENCE OF THE PHARMACEUTICAL
INDUSTRY: HEALTH POLICY, RESEARCH, PRESCRIBING PRACTICE AND PATIENT
USE
I am writing on behalf of the Royal Pharmaceutical
Society of Great Britain (RPSGB), the professional and regulatory
body for pharmacists. We welcome the opportunity to submit evidence
to this inquiry.
Please find attached six reports on direct-to-consumer
advertising (DTCA) of prescription medicines which were commissioned
by the RPSGB, and three responses we made to external consultations
on the topics of DTCA and information for patients.
1. Meek C (November 2001). Direct-to-consumer
advertising of prescription medicines: a review of international
policy and evidence. A report for the Royal Pharmaceutical Society
of Great Britain.
2. Meek C (November 2001). Recent developments
in DTCA.
3. Meek C (June 2002). Direct-to-consumer
advertising (DTCA) of prescription medicines: first quarterly
update—January to March 2002.
4. Meek C (September 2002). Direct-to-consumer
advertising of prescription medicines. Quarter 2 update, April
to June 2002.
5. Meek C (November 2002). Direct-to-consumer
advertising of prescription medicines: third quarterly update—July
to September 2002.
6. Meek C (January 2003). Direct-to-consumer
advertising (DTCA) of prescription medicines: fourth quarterly
update—October to December 2002.
7. RPSGB response to Consumers' Association
consultation on Shaping the future of patient information and
education, September 2002.
8. RPSGB response to MCA consultation on
Advertising medicines for use in pregnancy, August 2002.
9. RPSGB response to MCA consultation on
Disease awareness campaigns: draft guidelines,[10]
July 2002.
I hope this information will be useful to the
Committee.
12 August 2004
10 Not printed. Back
| 
